Molecular mechanisms of the ambroxol action in Gaucher disease and GBA1 mutation-associated Parkinson disease
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Ambroxol shows potential for treating Gaucher disease and Parkinson disease by increasing glucocerebrosidase (GCase) levels and activity through multiple mechanisms beyond chaperone action.
Area Of Science
- Biochemistry
- Genetics
- Pharmacology
Background
- Glucocerebrosidase (GCase), encoded by GBA1, is crucial for glycosphingolipid hydrolysis.
- GCase deficiency causes Gaucher disease; heterozygous GBA1 mutations are linked to Parkinson disease.
- Pharmacological chaperones are a therapeutic strategy for GCase-related disorders.
Purpose Of The Study
- To summarize ambroxol's multifaceted biological mechanisms of action.
- To explore ambroxol's efficacy in Gaucher disease and GBA1-associated Parkinson disease.
- To discuss ambroxol's impact on disease markers and symptoms.
Main Methods
- Review of studies on ambroxol's effects in cellular and animal models.
- Analysis of clinical data from patients.
- Evaluation of ambroxol's roles as a chaperone, ERAD modulator, autophagy inducer, and pain reliever.
Main Results
- Ambroxol increases GCase levels and activity.
- Evidence suggests ambroxol acts via multiple pathways, not solely as a chaperone.
- Ambroxol demonstrates potential in reducing disease markers and symptoms.
Conclusions
- Ambroxol exhibits diverse therapeutic mechanisms for GCase-related disorders.
- Understanding ambroxol's full action profile is key for optimized treatment strategies.
- Further research can guide appropriate therapy selection and dosing for ambroxol.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
The cephalic phase is a conditioned or learned response to familiar foods. Our appetite or desire for a particular food modifies the preparatory responses directed by the brain. Individuals may produce more saliva and stomach...
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...